Fairfield, Bush & Co’s Myriad Genetics MYGN Stock Holding History

Fairfield, Bush & Co’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-10,690	Closed	-$461K	–	138
2015 Q4	$461K	Buy	+10,690	New	+$452K	0.16%	96
2015 Q3	–	Sell	-12,344	Closed	-$420K	–	152
2015 Q2	$420K	Sell	12,344 -61,970	-83%	-$2.11M	0.13%	117
2015 Q1	$2.63M	Sell	74,314 -10,020	-12%	-$359K	0.77%	43
2014 Q4	$2.87M	Sell	84,334 -40,420	-32%	-$1.43M	0.82%	39
2014 Q3	$4.81M	Buy	124,754 +3,020	+2%	+$113K	1.38%	25
2014 Q2	$4.74M	Buy	121,734 +5,735	+5%	+$213K	1.39%	25
2014 Q1	$3.97M	Buy	+115,999	New	+$3.59M	1.87%	23

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Fairfield, Bush & Co's MYGN Position: Q1 2016 in Review

Fairfield, Bush & Co sold out of Myriad Genetics (MYGN) in Q1 2016, closing a stake of 10,690 shares — an estimated $461K sold.

Fairfield, Bush & Co first reported a position in MYGN in Q1 2014 and held it in 7 quarters. The position peaked at $4.81M in Q3 2014. 234 funds tracked by Wall St. Rank hold MYGN as of Q1 2016.

Fairfield, Bush & Co reported no remaining Myriad Genetics position as of Q1 2016 after selling out during the quarter.
Fairfield, Bush & Co sold 10,690 Myriad Genetics shares in Q1 2016, an estimated $461K.
Fairfield, Bush & Co first reported a position in Myriad Genetics in Q1 2014 and held it in 7 quarters.
Fairfield, Bush & Co's Myriad Genetics position peaked at $4.81M in Q3 2014.
234 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2016.

Based on Fairfield, Bush & Co's 13F filing for Q1 2016, filed 13 May 2016.